Comparing iShares Biotechnology ETF and iShares U.S. Healthcare ETF

TL/DR –

The iShares Biotechnology ETF (IBB) and iShares U.S. Healthcare ETF (IYH) offer different exposures within the healthcare sector – IBB is more concentrated on biotech companies, while IYH provides broader diversification in the healthcare sector, including pharmaceutical giants and medical equipment providers. IYH also has a lower expense ratio (0.37% compared to IBB’s 0.44%) and offers a higher yield, making it a more affordable choice for investors prioritizing income. However, IBB has outperformed IYH in recent times, but it comes with higher volatility due to its concentration in biotech, a sub-sector where results from a single clinical trial can significantly impact the fund.

iShares Biotechnology and U.S. Healthcare ETFs – A Comparative Analysis

The iShares Biotechnology ETF (NASDAQ:IBB) and the iShares U.S. Healthcare ETF (NYSEMKT:IYH) provide unique opportunities for investors looking to tap into the US healthcare market. IBB offers targeted exposure to biotech companies, whereas IYH grants broader diversification across the healthcare sector at a lesser cost.

Differences in Portfolio Composition and Performance

While IYH includes pharmaceutical giants and medical equipment providers, IBB focuses more on the high-growth, high-volatility biotechnology niche. The iShares U.S. Healthcare ETF emerges as the more affordable option with a 0.37% expense ratio, compared to 0.44% for the iShares Biotechnology ETF. Additionally, IYH provides a higher yield, which might attract income-focused investors.

Details on the ETFs’ Holdings

The iShares U.S. Healthcare ETF holds 100 positions, with major stakes in Eli Lilly, Johnson & Johnson, and Abbvie. In contrast, the iShares Biotechnology ETF is more concentrated, holding 243 positions with top holdings in Gilead Sciences, Amgen Inc, and Vertex Pharmaceuticals.

For more insights on ETF investing, consider this comprehensive guide.

Choosing the Right Healthcare ETF

The healthcare sector is currently experiencing a surge of investor interest, fueled by record dealmaking and a wave of biotech acquisitions. However, the choice between IBB and IYH depends on how much sector-specific risk an investor wishes to assume.

Final Evaluation

IBB’s superior performance in 2026 is attributed to strong biotech cycles and FDA approval activities. However, this comes with higher volatility and negligible dividends. On the other hand, IYH offers wider healthcare sector exposure, lower charges, and dividends, making it suitable for long-term investors seeking lower risk and income generation.

The 10 best stocks recently identified by the Stock Advisor analyst team do not include either of these ETFs. These 10 stocks are said to have potential for long-term growth with significant returns in the coming years.

See the 10 stocks for yourself and join an investing community built for the long haul.

—
Read More Health & Wellness News ; US News